Ozempic vs. Mounjaro vs. Therapeutic Ketosis: A Physician’s Honest Comparison

Every week in my clinic, a patient sits across from me and asks some version of the same question: “Doctor, should I just get on Ozempic?”

It’s a fair question. These drugs are everywhere — in the news, on social media, in celebrity interviews, and increasingly, in pharmacies across the country. And I want to be honest right from the start: they do work. My job isn’t to sell you on one approach. My job is to give you the full picture that most people — including most doctors — simply aren’t giving you.

So let’s talk about Ozempic, Mounjaro, and a third option that most people have never heard of but that I believe offers something the drugs fundamentally cannot: therapeutic ketosis — specifically, the physician-guided SKLeTT Protocol that I developed over decades of clinical practice. SKLeTT stands for Specific Ketone Level Titration Therapy — and that name tells you everything about what makes it different. It is not generic keto. It is a precisely calibrated, physician-monitored protocol in which your ketone levels are titrated to a specific therapeutic target and held there.

By the end of this article, you’ll understand exactly how each approach works, what the research says, what I see in real patients every week, and why the choice you make isn’t just about the number on the scale. It’s about your brain, your muscles, and the rest of your life.

What Are Ozempic and Mounjaro, Really?

Let’s start with the basics, because there’s a lot of confusion about what these drugs actually are — and what they aren’t.

Ozempic (generic name: semaglutide) is an injectable medication originally approved to treat Type 2 diabetes. Its main job is to mimic a hormone your gut naturally produces called GLP-1 — glucagon-like peptide-1. Think of GLP-1 as your body’s natural “I’m full, put the fork down” signal. It tells your brain to stop eating, slows down how quickly your stomach empties food, and helps regulate blood sugar. Ozempic essentially turns up the volume on that signal — dramatically.

The result? Less hunger. Less food intake. Weight loss — often significant weight loss.

Mounjaro (generic name: tirzepatide) does everything Ozempic does, but goes one step further. It mimics two gut hormones simultaneously: GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). Think of it this way: if Ozempic is a one-engine airplane, Mounjaro is a twin-engine jet. Both fly. One just flies faster and higher.

The clinical data backs this up. In head-to-head studies, patients on tirzepatide lost an average of 20% of their body weight compared to 14% for semaglutide — a clinically meaningful difference. In real-world data from over 18,000 patients, those on Mounjaro were three times more likely to achieve 15% weight loss compared to those on Ozempic.

These are genuinely impressive numbers. So why am I writing this article? Because the weight you lose is only part of the story. The type of weight you lose, what the drug does to your metabolism, and what happens when it stops — that’s the rest of the story.

What I See in My Own Clinic — Every Week

I work in a weight loss clinic where more than half my patients walk in asking for the injections. I understand why — the marketing is compelling, the celebrity endorsements are everywhere, and the promise of nearly effortless weight loss is genuinely appealing to someone who has struggled for years.

But here is what the advertisements don’t show you.

These medications suppress appetite so aggressively that patients often stop eating normally. That sounds like a feature. In practice, it is a serious metabolic problem. When you’re not hungry, you don’t just skip the junk food — you skip protein. And protein is the raw material your body uses to build and maintain muscle. Without adequate protein, your body begins quietly cannibalizing its own muscle tissue for energy. Most of my GLP-1 patients are, in effect, in a state of protein starvation while losing weight — and they don’t even realize it because the scale is moving in the right direction.

Here’s the second piece nobody talks about. When you’re not in ketosis — and these patients are not, because they’re still consuming carbohydrates — your brain runs primarily on glucose. When glucose dips, your brain screams for sugar. So even on a medication that kills your appetite for a full meal, patients still crave and consume carbohydrates. The diet quietly becomes carb-dominant by default. No protein. No protective fats. Mostly carbs. That is the opposite of a metabolically healthy eating pattern.

I want to be precise here, because I’m not speculating — I test my patients’ ketone levels. Patients on GLP-1 medications are virtually never in meaningful ketosis. The rare exceptions are young patients doing significant amounts of vigorous exercise. For the vast majority, blood ketones sit at or near zero.

The result of all this is predictable: the weight coming off is primarily water weight and glycogen — the stored form of carbohydrate that your muscles hold along with water molecules. When carb intake drops even modestly, that glycogen releases, the water follows, and the scale drops fast. It feels like success. Patients are thrilled.

Then the medication stops. And it stops for most patients because at $1,000–$1,500 per month, it simply isn’t affordable long-term.

The weight comes back — almost immediately. Within weeks. Sometimes within days. That rapid return is the clinical fingerprint of water weight loss. True fat loss, earned through genuine metabolic change, does not return overnight. But water does. And the muscle lost during the medication period doesn’t return on its own. Patients are left lighter on paper, metabolically worse off in reality, and more frustrated than when they started.

A Warning Nobody Is Publishing: GLP-1 Drugs May Block Your Ability to Enter Ketosis

Here is something I have not seen published anywhere in the medical literature — but that I have witnessed repeatedly in my own patients, and that every person considering GLP-1 therapy deserves to know.

It is not just that Ozempic and Mounjaro fail to produce ketosis. Based on my clinical experience, these medications appear to actively inhibit your body’s ability to enter ketosis — even after you stop taking them.

I have had multiple patients attempt to transition to the SKLeTT Protocol while still on GLP-1 injections. Every one of them struggled to form meaningful ketones. One patient — and this case was striking — could not produce ketones even two to three weeks after completely stopping the medication. That is not something I typically see in patients discontinuing other pharmaceuticals. It suggests that GLP-1 drugs may suppress the metabolic machinery responsible for ketogenesis in a way that outlasts the drug itself.

Here is the biology of why this likely happens. Ketone production — ketogenesis — occurs in the liver and requires two things: low insulin levels and elevated glucagon. GLP-1 agonists powerfully suppress glucagon, the hormone that signals the liver to start making ketones. Think of glucagon as the key that unlocks the liver’s ketone-production engine. Ozempic and Mounjaro essentially keep that key turned off. Even after the drug clears your system, the signaling pathways may take weeks to fully recover.

If you are currently on, or have recently been on, a GLP-1 medication and are considering therapeutic ketosis, please disclose this to your physician. The transition requires extra care, extended time, and careful monitoring. This is precisely why physician guidance in the SKLeTT Protocol is not optional. It is essential.

The Problem Nobody Is Talking About: What You’re Really Losing

When you lose weight through caloric restriction without ketosis, your body doesn’t distinguish cleanly between fat and muscle. It loses both — and GLP-1 drugs have a growing, documented muscle loss problem in the research literature.

A University of Virginia study published in 2025 found that GLP-1 medications “significantly reduce body weight and adiposity, along with substantial fat-free mass loss, but with no clear evidence of cardiorespiratory fitness enhancement.” The researchers warned this could take a serious toll on metabolic health, healthspan, frailty, and longevity. A separate 2025 study found that Ozempic-induced weight loss decreased lean mass by approximately 10%, with some skeletal muscles becoming weaker even when they didn’t visibly shrink.

Here’s why this matters beyond the gym. Muscle is your metabolic engine — it burns calories at rest, regulates blood sugar, protects your joints, and is one of the strongest predictors of how well you age and how long you live. When you lose muscle, your resting metabolism slows. When your metabolism slows, keeping weight off becomes exponentially harder. It is a physiological trap that the scale obscures completely.

Now here is the question I ask every new patient: did your prescribing doctor measure your muscle mass before starting you on Ozempic? Did they check your grip strength, your body composition, your functional fitness baseline? In almost every case the answer is no — because the entire clinical conversation begins and ends at the scale.

Why BHB Is the Missing Piece

This is where the science becomes genuinely exciting — and where therapeutic ketosis separates itself from every pharmaceutical approach.

Beta-hydroxybutyrate — BHB — is the primary ketone your body produces in true ketosis. Most people think of it as brain fuel, and it is exceptional brain fuel. But BHB is also a powerful muscle-preserving and muscle-building signal with multiple simultaneous mechanisms that no drug currently replicates.

When BHB is present in your bloodstream at therapeutic levels, it:

In plain language: BHB sends your body a powerful message — “we have fuel, we don’t need to cannibalize the furniture.” Without BHB — which is exactly the situation my GLP-1 patients are in, as confirmed by direct ketone testing — there is no muscle protection signal. The appetite suppression takes calories away, but nothing steps in to tell the body to spare lean tissue. So the body doesn’t spare it.

This is almost certainly the primary reason GLP-1 drugs cause disproportionate lean mass loss. It is not an inevitable consequence of weight loss. It is the predictable consequence of weight loss without ketosis.

The Brain Problem: Where These Drugs Fall Short Most

For patients who come to me because of brain fog, memory slips, mental fatigue, and early cognitive decline, the GLP-1 conversation must go further than weight.

There was genuine excitement in the research community that semaglutide might help with Alzheimer’s disease. Early observational data looked promising. Then the randomized controlled trial results arrived — and a major clinical trial of semaglutide for early Alzheimer’s disease failed to demonstrate meaningful improvements in cognition or daily functioning. This wasn’t a marginal miss. It was a clear failure to move the needle on what matters most: how well the brain actually works.

The reason is mechanistic. The fundamental problem in Alzheimer’s and progressive cognitive decline is not only inflammation or dysregulated blood sugar — it is a brain energy crisis. The aging, insulin-resistant brain progressively loses its ability to efficiently burn glucose. Think of it as a power plant whose primary fuel line is slowly corroding. GLP-1 drugs improve how the body processes insulin peripherally, but they provide no alternative fuel source for a brain that can no longer run efficiently on glucose.

BHB does exactly that. In therapeutic ketosis, BHB crosses the blood-brain barrier freely and is metabolized directly by brain cells — including cells that have lost the ability to use glucose. Early studies of ketogenic therapy for cognitive impairment demonstrate improvements in brain energy metabolism on PET imaging, better scores on memory and attention tests, and reduced neuroinflammatory markers.

Therapeutic Ketosis vs. Regular Keto: A Critical Distinction

I need to draw a sharp line here, because “keto” has become a heavily marketed brand — and most of what is sold under that label has very little to do with what I’m describing.

The keto diet you read about on social media is typically a high-fat, low-carbohydrate eating pattern that someone attempts for a few weeks, loses some water weight, hits a plateau, misses bread, and abandons. Many people on so-called keto diets never actually reach meaningful ketosis because they’re still consuming too many carbohydrates. I test these patients too. Their blood ketones are near zero.

Specific Ketone Level Titration Therapy is something categorically different. It is a clinically monitored metabolic state in which blood ketones are measured regularly and titrated — adjusted precisely — to reach and maintain a therapeutic target level. It is not a diet. It is a medical protocol.

The Dependency Trap

Let’s address something the pharmaceutical industry doesn’t lead with in its marketing materials. Most people who stop taking Ozempic or Mounjaro regain a substantial portion — sometimes nearly all — of the weight they lost. This is not personal failure or lack of willpower. It is the expected pharmacological result of removing an external hormonal signal the body has been depending on. Hunger returns, often intensely. The metabolism, already slowed by muscle mass lost during treatment, is now less capable of managing caloric intake than it was before the drug was started.

This is the weight cycling trap — a pattern of loss and regain that, over time, may cause more cumulative harm to long-term metabolic health than sustained moderate excess weight.

Therapeutic ketosis, when properly implemented and maintained, does not create this dependency. You are not borrowing a hormone signal from a pharmaceutical company at $1,200 per month. You are restructuring your own metabolism — teaching your body to run efficiently on a fuel system it already has the equipment to produce. The changes are durable because they are biological, not pharmaceutical.

A Note on Exercise and Brain Energy

Most people think exercise matters for weight loss because it burns calories. That is true, but it is almost beside the point. The real reason I insist on exercise for every patient in my program is neurological. Exercise keeps brain energy high. And when brain energy is high, you don’t stress eat. You don’t reach for comfort food at 10pm after a hard day. You simply don’t need to.

Have you ever noticed that genuinely athletic people don’t stress eat? It’s not willpower or moral superiority. It’s brain chemistry. A brain running at full energy doesn’t generate the low-level anxiety and irritability that most sedentary adults live with constantly — the feeling that creates the subconscious drive to reach for something sweet or comforting. That drive isn’t a character flaw. It is a metabolic symptom, and it is reversible.

I have interrogated every patient who ever came back to me having regained significant weight. Without exception, the sequence is the same: exercise stopped first — a gym closure, an illness, a family obligation — and then, weeks later, the eating patterns deteriorated. The dietary failure was always downstream of the neurological one. GLP-1 drugs address none of this. The SKLeTT Protocol addresses it directly.

My Honest Clinical Position

But if you are willing to do things the right way, I will teach you. And in more than 30 years of practice, the patients I have watched achieve durable, transformative results — not just on the scale but in their energy, their cognition, their mood, their quality of life — are the ones who committed to restructuring their metabolism rather than borrowing a pharmaceutical signal.

Head-to-Head Comparison

References